Patents by Inventor Jonathan Rohll
Jonathan Rohll has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100273996Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pot proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pot proteins is codon optimised for expression in the producer cell.Type: ApplicationFiled: October 2, 2009Publication date: October 28, 2010Inventors: Alan John Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos A. Mitrophanous
-
Publication number: 20090111106Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.Type: ApplicationFiled: July 7, 2008Publication date: April 30, 2009Inventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Mary Kingsman
-
Publication number: 20080269473Abstract: A method of producing a replication defective retrovirus comprising transfecting a producer cell with the following: iii) a retroviral genome; iv) a nucleotide sequence coding for retroviral gag and pol proteins; and iii) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (ii); characterised in that the nucleotide sequence coding for retroviral gag and pol proteins is codon optimised for expression in the producer cell.Type: ApplicationFiled: March 20, 2008Publication date: October 30, 2008Inventors: Alan John Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos A. Mitrophanous
-
Patent number: 7419829Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.Type: GrantFiled: June 21, 2004Date of Patent: September 2, 2008Assignee: Oxford BioMedica (UK) LimitedInventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Marie Kingsman
-
Patent number: 7259015Abstract: Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.Type: GrantFiled: April 7, 2003Date of Patent: August 21, 2007Assignee: Oxford Biomedia (UK) LimitedInventors: Alan John Kingsman, Nicholas D. Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
-
Publication number: 20070025970Abstract: The present invention relates to retroviral vector genomes and to vector systems comprising such genomes. In particular the present invention relates to a retroviral vector genome comprising two or more NOIs operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and optionally Aromatic Amino Acid Dopa Decarboxylase.Type: ApplicationFiled: July 14, 2006Publication date: February 1, 2007Inventors: Alan Kingsman, Nicholas Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
-
Publication number: 20060024274Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.Type: ApplicationFiled: June 15, 2005Publication date: February 2, 2006Inventors: Alan Kingsman, Miles Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
-
Patent number: 6969598Abstract: A method for producing viral vectors is described using packaging and producer cell lines is described. The producer cell comprises: (i) a first nucleotide sequence (NS) encoding a toxic viral envelope protein operably linked to a promoter; wherein the promoter is operably linked to at least one copy of a TRE; (ii) a second NS wherein the second NS comprises a sequence encoding a tetracycline modulator; (iii) a third NS encoding a retrovirus nucleocapsid protein; and (iv) a fourth NS comprising a retroviral sequence capable of being encapsidated in the nucleocapsid protein such that the retroviral vector particle titre obtainable from the producer cell is regulatable by tetracycline and an initial stimulus with sodium butyrate or functional analogues thereof.Type: GrantFiled: April 30, 2002Date of Patent: November 29, 2005Assignees: Oxford Biomedica (UK) Limited, The University of North Carolina at Chapel HillInventors: John C. Olsen, Kyriacos Andreou Mitrophanous, Jonathan Rohll, Alan John Kingsman, Fiona Margaret Ellard
-
Publication number: 20050260164Abstract: Provided is an improved method for controlling gene expression in vivo through the use of a gene switch comprising one or more aptamer sequences operably linked to or incorporated into the untranslated regions (UTRs) of a transgene or nucleotide sequence of interest. Also provided are expression vectors having aptamer sequences located within the 3? UTR, the 5? UTR and between the genes of a multicistronic mRNA, as well as methods of using the expression vectors for controlling or regulating gene expression.Type: ApplicationFiled: April 8, 2005Publication date: November 24, 2005Inventors: Doug Jolly, Jonathan Rohll, Bernd Buehler, Kyri Mitrophanous, Pippa Radcliffe
-
Publication number: 20050042234Abstract: Provided herein are methods for producing a replication defective retrovirus, which comprises transfecting a producer cell with (1) a retroviral genome; (2) a nucleotide sequence coding for retroviral gag and pol proteins that is codon-optimized for expression in the producer cell; and (3) nucleotide sequences encoding other essential viral packaging components not encoded by the nucleotide sequence of (1).Type: ApplicationFiled: April 18, 2001Publication date: February 24, 2005Inventors: Alan Kingsman, Narry Kim, Ekaterini Kotsopoulou, Jonathan Rohll, Kyriacos Mitrophanous
-
Publication number: 20050002907Abstract: The present invention provides a vector system comprising a mutated post-transcriptional regulatory element. In particular, the present invention relates to a mutated WPRE sequence that can efficiently express nucleotides of interest in a retroviral vector system. The present invention also relates to methods of delivering and expressing nucleotides of interest to a target cell.Type: ApplicationFiled: June 21, 2004Publication date: January 6, 2005Inventors: Kyri Mitrophanous, Jonathan Rohll, James Miskin, Susan Kingsman
-
Publication number: 20040013648Abstract: Provided are retroviral vector genomes and vector systems comprising the genomes. In particular, a retroviral vector genome comprising two or more NOIs, operably linked by one or more Internal Ribosome Entry Site(s); a lentiviral vector genome comprising two or more NOIs suitable for treating a neurodegenerative disorder; and a lentiviral vector genome which encodes tyrosine hydroxylase, GTP-cyclohydrolase I and, optionally, Aromatic Amino Acid Dopa Decarboxylase are provided.Type: ApplicationFiled: April 7, 2003Publication date: January 22, 2004Inventors: Alan John Kingsman, Nicholas D. Mazarakis, Enca Martin-Rendon, Mimoun Azzouz, Jonathan Rohll
-
Publication number: 20030147907Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.Type: ApplicationFiled: May 29, 2001Publication date: August 7, 2003Inventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim
-
Publication number: 20030143205Abstract: An alpha-lentivirus vector comprising at least one alphaviral component and at least one lentiviral component, wherein the lentiviral component is capable of being packaged into a lentiviral particle after introduction of said vector into a human cell.Type: ApplicationFiled: July 22, 2002Publication date: July 31, 2003Applicant: Oxford Biomedica (UK) LimitedInventors: Jason Slingsby, Kyriacos Mitrophanous, Jonathan Rohll, Alison Lawrie
-
Publication number: 20030113898Abstract: A method for producing viral vectors is described using packaging and producer cell lines is described. The producer cell comprises: (i) a first nucleotide sequence (NS) encoding a toxic viral envelope protein operably linked to a promoter; wherein the promoter is operably linked to at least one copy of a TRE; (ii) a second NS wherein the second NS comprises a sequence encoding a tetracycline modulator; (iii) a third NS encoding a retrovirus nucleocapsid protein; and (iv) a fourth NS comprising a retroviral sequence capable of being encapsidated in the nucleocapsid protein such that the retroviral vector particle titre obtainable from the producer cell is regulatable by tetracycline and an initial stimulus with sodium butyrate or functional analogues thereof.Type: ApplicationFiled: April 30, 2002Publication date: June 19, 2003Applicant: Oxford Biomedica (UK) LimitedInventors: John C. Olsen, Kyriacos Andreou Mitrophanous, Jonathan Rohll, Alan John Kingsman, Fiona Margaret Ellard
-
Publication number: 20020034393Abstract: A retroviral vector capable of delivering an NOI and comprising an exogenous second synthesis element.Type: ApplicationFiled: May 18, 2001Publication date: March 21, 2002Inventors: Kyriacos A. Mitrophanous, Mark Uden, Jonathan Rohll, Susan Mary Kingsman, Alan John Kingsman
-
Patent number: 6312683Abstract: A retroviral vector derived from a non-primate lentivirus genome comprising a deleted gag gene wherein the deletion in gag removes one or more nucleotides downstream of nucleotide 350 of the gag coding sequence.Type: GrantFiled: January 27, 1999Date of Patent: November 6, 2001Assignee: Oxford Biomedica (UK) LimitedInventors: Alan John Kingsman, Miles William Carroll, Jonathan Rohll, Kyriacos Mitrophanous, Narry Kim